Perioperative antibiotics and anti-inflammatory agents in cataract surgery

Current Opinion in Ophthalmology

Volumn 19, Issue 1, 2008, Pages 22-26

  DeCroos, Francis Char ^a   Afshari, Natalie A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antibacterial agents; Cataract extraction; Corticosteroid; Endophthalmitis; Nonsteroidal anti inflammatory agent

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; BROMFENAC; CEFAZOLIN; CEFUROXIME; CEPHALOSPORIN; CORTICOSTEROID; DICLOFENAC; GATIFLOXACIN; KETOROLAC; LEVOFLOXACIN; MOXIFLOXACIN; NEPAFENAC; NONSTEROID ANTIINFLAMMATORY AGENT; OFLOXACIN; PLACEBO; PREDNISOLONE; QUINOLONE DERIVATIVE; RIMEXOLONE; VANCOMYCIN;

ANTIBIOTIC THERAPY; CATARACT EXTRACTION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COMPARATIVE STUDY; CORTICOSTEROID THERAPY; DRUG EFFICACY; ENDOPHTHALMITIS; EUROPE; HUMAN; INCIDENCE; INFECTION PREVENTION; PERIOPERATIVE PERIOD; POSTOPERATIVE INFLAMMATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA MACULA CYSTOID EDEMA; RETROSPECTIVE STUDY; REVIEW; TREATMENT DURATION; UNITED STATES;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; ANTIBIOTIC PROPHYLAXIS; CATARACT EXTRACTION; ENDOPHTHALMITIS; HUMANS; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; TREATMENT OUTCOME;

EID: 37349001956     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e3282f30577     Document Type: Review

References (30)

1. Taban M, Behrens A, Newcomb RL, et al. Acute endophthalmitis following cataract surgery: a systematic review of the literature. Arch Ophthalmol 2005; 123:613-620.
2. West ES, Behrens A, McDonnell PJ, et al. The incidence of endophthalmitis after cataract surgery among the U.S. Medicare population increased between 1994 and 2001. Ophthalmology 2005; 112:1388-1394.
3. Barry P, Seal DV, Gettinby G, et al. ESCRS study of prophylaxis of postoperative endophthalmitis after cataract surgery: preliminary report of principal results from a European multicenter study. J Cataract Refract Surg 2006; 32:407-410. Preliminary data from the ESCRS group strongly supports the efficacy of intracameral cefuroxime for endophthalmitis prophylaxis.
4. Speaker MG, Menikoff JA. Prophylaxis of endophthalmitis with topical povidone-iodine. Ophthalmology 1991; 98:1769-1775.
5. Ou JI, Ta CN. Endophthalmitis prophylaxis. Ophthalmol Clin North Am 2006; 19:449-456.
6. Rowen S. Preoperative and postoperative medications used for cataract surgery. Curr Opin Ophthalmol 1999; 10:29-35.
7. Abel R Jr, Abel AD. Perioperative antibiotic, steroid, and nonsteroidal anti-inflammatory agents in cataract intraocular lens surgery. Curr Opin Ophthalmol 1997; 8:29-32.
8. Seal DV, Barry P, Gettinby G, et al. ESCRS study of prophylaxis of postoperative endophthalmitis after cataract surgery: case for a European multicenter study. J Cataract Refract Surg 2006; 32:396-406. Preliminary data from the ESCRS group strongly support the efficacy of intracameral cefuroxime for endophthalmitis prophylaxis.
9. Ta CN, Chang RT, Singh K, et al. Antibiotic resistance patterns of ocular bacterial flora: a prospective study of patients undergoing anterior segment surgery. Ophthalmology 2003; 110:1946-1951.
10. Chang D. Cataract Clinical Committee Survey on Antibiotic Usage: TASS and Endophthalmitis Symposium. Proceedings of the ASCRS Symposium on Cataract, IOL and Refractive Surgery; 27 April-2 May 2007; San Diego, CA. ASCRSMedia; 2007.
11. Lundstrom M, Wejde G, Stenevi U, et al. Endophthalmitis after cataract surgery: a nationwide prospective study evaluating incidence in relation to incision type and location. Ophthalmology 2007; 114:866-870. Prospective study from Sweden demonstrates low incidence of endophthalmitis after cataract surgery, possibly because intracameral cefuroxime is routinely used.
12. Romero P, Mendez I, Salvat M, et al. Intracameral cefazolin as prophylaxis against endophthalmitis in cataract surgery. J Cataract Refract Surg 2006; 32:438-441.
13. Ng JQ, Morlet N, Bulsara MK, et al. Reducing the risk for endophthalmitis after cataract surgery: population-based nested case-control study: endophthalmitis population study of Western Australia sixth report. J Cataract Refract Surg 2007; 33:269-280. Retrospective case-control study from Western Australia reports subconjunctival injection of antibiotics reduces risk of endophthalmitis.
14. Wallin T, Parker J, Jin Y, et al. Cohort study of 27 cases of endophthalmitis at a single institution. J Cataract Refract Surg 2005; 31:735-741.
15. Moshirfar M, Feiz V, Vitale AT, et al. Endophthalmitis after uncomplicated cataract surgery with the use of fourth-generation fluoroquinolones: a retrospective observational case series. Ophthalmology 2007; 114:686-691. Retrospective observational study reports overall low rate of endophthalmitis when topical moxifloxacin or gatifloxacin used as prophylaxis.
16. Axer-Siegel R, Stiebel-Kalish H, Rosenblatt I, et al. Cystoid macular edema after cataract surgery with intraocular vancomycin. Ophthalmology 1999; 106:1660-1664.
17. Moshirfar M, Mirzaian G, Feiz V, et al. Fourth-generation fluoroquinolone-resistant bacterial keratitis after refractive surgery. J Cataract Refract Surg 2006; 32:515-518.
18. Deramo VA, Lai JC, Fastenberg DM, et al. Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin. Am J Ophthalmol 2006; 142:721-725. Report that endophthalmitis can develop after cataract surgery despite prophylactic use of fourth-generation fluoroquinolones. This study also reports bacterial isolates resistant to gatifloxacin and moxifloxacin.
19. Novack GD, Howes J, Crockett RS, et al. Change in intraocular pressure during long-term use of loteprednol etabonate. J Glaucoma 1998; 7:266-269.
20. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group. Am J Ophthalmol 1999, 127:537-544.
21. Heier JS, Topping TM, Baumann W, et al. Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology 2000; 107:2034-2038; discussion 2039.
22. Donnenfeld ED, Perry HD, Wittpenn JR, et al. Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic-response curve. J Cataract Refract Surg 2006; 32:1474-1482. Certain preoperative ketorolac regmines can reduce inflammation after cataract surgery relative to placebo or a shorter ketorolac regimen.
23. Shimura M, Nakazawa T, Yasuda K, et al. Diclofenac prevents an early event of macular thickening after cataract surgery in patients with diabetes. J Ocul Pharmacol Ther 2007; 23:284-291.
24. Holzer MP, Solomon KD, Sandoval HP, et al. Comparison of ketorolac tromethamine 0.5% and loteprednol etabonate 0.5% for inflammation after phacoemulsification: prospective randomized double-masked study. J Cataract Refract Surg 2002; 28:93-99.
25. Solomon KD, Vroman DT, Barker D, et al. Comparison of ketorolac tromethamine 0.5% and rimexolone 1% to control inflammation after cataract extraction: prospective randomized double-masked study. J Cataract Refract Surg 2001; 27:1232-1237.
26. Hirneiss C, Neubauer AS, Kampik A, et al. Comparison of prednisolone 1%, rimexolone 1% and ketorolac tromethamine 0.5% after cataract extraction: a prospective, randomized, double-masked study. Graefes Arch Clin Exp Ophthalmol 2005; 243:768-773.
27. Sivaprasad S, Bunce C, Wormald R. Nonsteroidal anti-inflammatory agents for cystoid macular oedema following cataract surgery: a systematic review. Br J Ophthalmol 2005; 89:1420-1422.
28. Ke TL, Graff G, Spellman JM, et al. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation 2000; 24:371-384.
29. Lane SS, Modi SS, Lehmann RP, et al. Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. J Cataract Refract Surg 2007; 33:53-58. Preoperative nepafenac can reduce inflammation after cataract surgery relative to placebo.
30. Donnenfeld ED, Holland EJ, Stewart RH, et al. Bromfenac ophthalmic solution 0.09%(Xibrom) for postoperative ocular pain and inflammation. Ophthalmology 2007; 114:1653-1662. Postoperative bromfenac can reduce inflammation in patients after cataract surgery relative to placebo.